AOBiome's B244 demonstrated positive results from its Phase 2b …
2022年2月22日 · AOBiome Therapeutics, a clinical stage biotechnology company focused on transforming human health by developing topical biologic therapies for systemic inflammatory conditions, announced positive pivotal Phase 2b results from its trial evaluating B244 in both pruritus (itch) and appearance of atopic dermatitis (eczema). The trial enrolled 547 patients …
AOBiome Completes Patient Enrollment In Phase 2 Clinical Trial Of …
2017年4月13日 · First-in-Class Therapy Designed to Deliver Nitric Oxide for Application in Diverse Inflammatory Conditions AOBiome, a clinical-stage life sciences company advancing patented microbiome-targeted therapies for systemic and local inflammatory conditions, announced today completion of patient enrollment in the Company’s Phase 2 clinical trial of its lead product …
AOBiome announces the publication of positive Phase 2b results …
2023年5月16日 · The peer-reviewed publication describes the significant effects of B244 in 4 weeks across key endpoints in adult patients with atopic dermatitis and associated pruritus (itch) in the largest study of B244 to date. The study demonstrated significant efficacy of B244 across all clinical endpoints, including the improvement of itch, eczema severity, and quality of life […]
Home - AOBiome
2024年1月30日 · AOBiome is a world-leading clinical-stage microbiome company focusing on research and development of therapeutics for inflammatory conditions, central nervous system disorders and other diseases. Our proprietary product candidates harness a strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria, or AOB, a human commensal with well …
Pipeline - AOBiome
We have completed six Phase 2 clinical programs and multiple pre-clinical programs. Over 1,700 patients have been enrolled in our clinical trials since 2016. Regardless of dose, mode of delivery, indication targeted, or age of patients, our bacterial drug candidate B244 has been very well tolerated with an adverse event profile that is equal to […]
Additional Study Augments the Results of AOBiome's Successful …
2022年9月20日 · The additional study showed the MoA related to patients’ continued improvement of itch over time as also observed in the Phase 2b study, which saw an increase from 34.0% at 4 weeks to 40.9% itch reduction at 8 weeks.
AOBiome Doses First Patient in Phase 1b Clinical Trial of B244 for …
2019年3月6日 · Data from its First Pediatric Study are Anticipated in the Second Half of 2019 CAMBRIDGE, Mass., March 6, 2019 /PRNewswire/ — AOBiome Therapeutics, Inc. (“AOBiome”), a leading clinical-stage microbiome company focusing on the research and development of therapeutics for dermatological conditions, migraine, hypertension and other systemic …
AOBiome Therapeutics Granted Composition of Matter Patent for …
2023年4月6日 · The newly issued patent covers Composition of Matter for AOBiome’s proprietary strain of Ammonia Oxidizing Bacteria (AOB), along with additional claims pertaining to a variety of related methods including use thereof in changing a composition of a skin microbiome of a subject, inhibiting microbial growth on a subject’s skin, and treating or preventing a skin […]
USPTO Grants AOBiome Therapeutics Composition of Matter …
2024年10月9日 · The newly issued patent covers Composition of Matter for AOBiome’s proprietary strain of Ammonia Oxidizing Bacteria (AOB), along with additional claims pertaining to a variety of related methods including use thereof in changing a composition of a skin microbiome of a subject, inhibiting microbial growth on a subject’s skin, and treating or preventing a skin […]
Clinical Trials and Results - AOBiome
The ability to treat moderate to severe itch quickly without needing moderate to severe drugs, which are either expensive or have a risky safety profile, presents B-244 with a unique market opportunity. These benefits were provided by a topical biologic spray with an extremely advantageous safety profile.